The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
BACKGROUND:Ribonucleotide reductase M1 (RRM1) is an important molecule in different types of cancer. The objective of this study was to evaluate the predictive roles of RRM1 in the survival of patients with resectable pancreatic adenocarcinoma who received treatment with gemcitabine or nongemcitabine adjuvant therapy.
METHODS:In total, 122 patients underwent tumor resection for pancreatic adenocarcinoma...
BACKGROUND:Only 2 prospective studies have previously reported prognostic factors for anal cancer, European Organization for Research and Treatment of Cancer trial 22861 (EORTC 22861) and Radiation Therapy Oncology Group trial 98‐11 (RTOG 98‐11). Both of those trials reported that clinically positive lymph nodes and male sex predicted poorer overall survival (OS). The EORTC 22861 trial indicated that...
BACKGROUND:Recent studies have demonstrated the feasibility of combining oxaliplatin with 5‐fluorouracil (5‐FU) or capecitibine and radiation therapy. The addition of bevacizumab to chemotherapy improves overall survival for metastatic disease. We initiated a phase 2 trial to evaluate preoperative capecitabine, oxaliplatin, and bevacizumab with radiation therapy followed by surgery and postoperative...
BACKGROUNDThis study sought to determine the feasibility and recommended phase 2 dose (RP2D) of the combination of cetuximab with chemoradiotherapy based on 5‐fluorouracil (5‐FU) and cisplatin (CP) in locally advanced anal canal carcinoma.
METHODSCetuximab was administered on days 1, 8, 15, 29, 36, 43, and 50 (400 mg/m2 initial dose, then 250 mg/m2/week) concurrent with total dose radiation of 55...
BACKGROUNDWeekly or daily cisplatin and 5‐fluorouracil (5‐FU)‐based chemoradiation was evaluated for patients with locally advanced squamous cell carcinoma (SCC) of the anal canal treated at a single institution over a 20‐year period.
METHODSA retrospective, single‐institution analysis was conducted of patients receiving concurrent 5‐FU/cisplatin and radiotherapy for locally advanced SCC from 1989...
BACKGROUNDThe current study was conducted to determine whether quantified pathologic response assessed as a percentage of residual tumor cells is predictive of recurrence‐free survival (RFS) in patients with rectal cancer.
METHODSThe authors studied 251 patients with rectal adenocarcinoma who were treated with neoadjuvant chemoradiation and radical resection. Quantified pathologic response was defined...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.